

Temasek backs \$90M funding for JW Therapeutics

10 March 2018 | News | By Manbeena Chawla

The latest financing will help the team further advance the JWCAR029 clinical programme.



A consortium of leading global investors including Temasek and Sequoia Capital China has joined the \$90-million Series A financing round of Shanghai-based biotech startup JW Therapeutics.

Others investors who joined the round include YuanMing Capital, Oriza Seed Capital, Yipu Capital, AVICT Global Holdings. Existing investors WuXi AppTec Group and Juno Therapeutics also participated in the round.

The latest financing will help the team further advance the JWCAR029 clinical programme, develop a therapeutic pipeline and build a new commercial manufacturing facility.

The startup mainly focuses on leading cell-based therapy technologies. JW Therapeutics' recent developments include JWCAR029, a CAR-T therapy (emerging form of cancer treatment, primarily for blood cancers like leukaemia) for treatment of B-cell (a type of white blood cell) malignancies.